The COVID-19 Impact on the Trends in Yellow Fever and Lassa Fever Infections in Nigeria.

Infect Dis Rep

Cancer and Infectious Disease Epidemiology Research Unit (CIDERU), College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa.

Published: November 2022

Lassa fever (LF) and yellow fever (YF) belong to a group of viral hemorrhagic fevers (VHFs). These viruses have common features and damages the organs and blood vessels; they also impair the body's homeostasis. Some VHFs cause mild disease, while some cause severe disease and death such as in the case of Ebola or Marburg. LF virus and YF virus are two of the most recent emerging viruses in Africa, resulting in severe hemorrhagic fever in humans. Lassa fever virus is continuously on the rise both in Nigeria and neighboring countries in West Africa, with an estimate of over 500,000 cases of LF, and 5000 deaths, annually. YF virus is endemic in temperate climate regions of Africa, Central America (Guatemala, Honduras, Nicaragua, El Salvador), and South America (such as Brazil, Argentina, Peru, and Chile) with an annual estimated cases of 200,000 and 30,000 deaths globally. This review examines the impact of the COVID-19 pandemic on the trend in epidemiology of these two VHFs to delineate responses that are associated with protective or pathogenic outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680345PMC
http://dx.doi.org/10.3390/idr14060091DOI Listing

Publication Analysis

Top Keywords

lassa fever
12
yellow fever
8
fever
6
covid-19 impact
4
impact trends
4
trends yellow
4
fever lassa
4
fever infections
4
infections nigeria
4
nigeria lassa
4

Similar Publications

Introduction: Lassa fever (LF), a public health problem of great importance endemic in West Africa, is an acute and sometimes fatal viral haemorrhagic disease which leads to mortality. The current study assessed the knowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.

Methods: Descriptive study design and Cross sectional study design was used for this study.

View Article and Find Full Text PDF

Current perspectives on vaccines and therapeutics for Lassa Fever.

Virol J

December 2024

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.

View Article and Find Full Text PDF

Descriptive epidemiology of Lassa fever, its trend, seasonality, and mortality predictors in Ebonyi State, South- East, Nigeria, 2018-2022.

BMC Public Health

December 2024

Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria.

Background: Nigeria is an epicenter for Lassa fever. Ebonyi state is located in the South-Eastern region of Nigeria where a high burden of Lassa fever has been reported. Therefore, this study was designed to assess the epidemiology of Lassa fever, its seasonality, trend, and mortality predictors in Ebonyi state, South-East, Nigeria.

View Article and Find Full Text PDF

Systematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.

Am J Trop Med Hyg

December 2024

Department of Medicine, Section of Infectious Diseases, School of Medicine, Tulane University, New Orleans, Louisiana.

Article Synopsis
  • The systematic review focuses on reproductive health issues faced by female survivors of Lassa fever and Ebola virus disease.
  • Thirteen studies reviewed predominantly highlight negative outcomes related to reproductive health among EVD survivors, including menstrual irregularities and pregnancy loss, with no research identified on LF survivors.
  • The analysis indicates that about 14% of female EVD survivors experience adverse reproductive health outcomes, revealing a significant need for further research in this area.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!